At the 2024 Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, and affinity/kinetics determination using various biophysical techniques, as well as paratope and epitope mapping …Read More >

Benefiting from 15 years of expertise in protein production, the Protein Science platform in WuXi Biology has successfully served hundreds of global clients. Our protein science specialists at the Munich and Suzhou sites are at the forefront of international drug discovery efforts, offering a wide range of services, including protein production and various techniques of …Read More >

The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target.  The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use.  To support the development of next-generation …Read More >

Learn about our semi-automated chromatography platform for parallel purification of high-quality therapeutic targets.  At PEGS Europe 2023, WuXi AppTec scientists described an automated workflow integrated with a serial size exclusion platform, resulting in a complete purification scheme for the rapid purification of high-quality proteins expressed in E. coli, insect cells, and mammalian cells.  This approach …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to bind to the catalytic domain of KRAS. However, recent studies have found that KRAS mutants can also be targeted by heterogeneous sites, to develop covalent inhibitors of KRAS mutants. The discovery of inhibitors that selectively …Read More >